Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3494214 | 0.98 | OPRD1 (0.43) | OPRD1KCNH2OPRK1CYP2D6MAPT | |
| SCHEMBL22389768 | 0.78 | HDAC3 (0.50) | OPRD1KCNH2OPRK1CYP2D6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3228756 | 0.76 | HDAC3 (0.49) | OPRD1KCNH2OPRK1CYP2D6ALDH1A1 | |
| SCHEMBL2586824 | 0.76 | OPRD1 (0.44) | OPRD1KCNH2OPRK1CYP2D6MAPT | |
| SCHEMBL14918914 | 0.74 | OPRD1 (0.40) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL2590441 | 0.73 | OPRD1 (0.39) | OPRD1KCNH2OPRK1CYP2D6MAPT | |
| SCHEMBL14919156 | 0.72 | OPRD1 (0.39) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL3492810 | 0.71 | GPR119 (0.42) | — | |
| SCHEMBL3492815 | 0.71 | GPR119 (0.42) | — | |
| SCHEMBL14919240 | 0.70 | OPRD1 (0.35) | OPRD1KCNH2OPRK1CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | OPRD1 4498/4885KCNH2 2511/4885OPRK1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.